UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 11, 2024

BioRestorative Therapies, Inc.

(Exact name of registrant as specified in its charter)

Nevada	**001-37603**	**30-1341024**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

40 Marcus Drive Melville, New York	**11747**
(Address of principal executive offices)	(Zip code)

Registrant's telephone number, including area code (631) 760-8100

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
BRTX	BRTX	NASDAQ Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 **Regulation FD Disclosure**.

On March 11, 2024, BioRestorative Therapies, Inc. (the "Company") issued a press release (the "Press Release") announcing that the Company will be participating at the 36th Annual ROTH Conference being held March 17 to 19, 2024 at the Ritz Carlton, Laguna Niguel, Dana Point, California. A copy of the Press Release is furnished as Exhibit 99.1 hereto.

At the conference, Lance Alstodt, the Company's Chief Executive Officer, is scheduled to participate in a fireside chat. Certain presentation materials (the "Presentation Materials") may be utilized in connection with the chat. A copy of the Presentation Materials is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company may use the Presentation Materials, possibly with modification, in other presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an interest in the Company and its business.

The information referenced under this Item 7.01 (including Exhibits 99.1 and 99.2 referenced in Item 9.01 below) of this Current Report on Form 8-K is being "furnished" under "Item 7.01. Regulation FD Disclosure" and, as such, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information set forth in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 referenced in Item 9.01 below) shall not be incorporated by reference into any registration statement, report or other document filed by the Company pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 **Financial Statements and Exhibits**.

(d) Exhibits.

Number	Description
99.1	Press release, dated March 11, 2024, issued by BioRestorative Therapies, Inc.
99.2	Presentation Materials
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIORESTORATIVE THERAPIES, INC.

Dated: March 12, 2024

By: /s/ Lance Alstodt
Lance Alstodt
President and CEO

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (NASDAQ:BRTX**)**, a clinical stage company focused on stem cell-based therapies, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 at the Ritz Carlton, Laguna Niguel in Dana Point, California

BioRestorative's Chief Executive Officer, Lance Alstodt, is scheduled to participate in a fireside chat hosted by Jonathan Aschoff, Ph.D., Managing Director, Senior Research Analyst at ROTH MKM, on Monday, March 18, 2024 at 12:00pm PDT.

The fireside chat will be broadcast live and archived on the investor section of the Company's website at https://www.biorestorative.com/investor-relations.

Mr. Aschoff and other members of the Company's management team will also participate in a series of one-on-one meetings with investors during the conference. To arrange a meeting with BioRestorative, attending investors are encouraged to contact thier ROTH MKM sales representative or email oneononerequests@roth.com.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, *BRTX-100,* is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The *BRTX-100* production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, *BRTX-100* is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using *BRTX-100* to treat chronic lower back pain arising from degenerative disc disease.

• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Email: ir@biorestorative.com

biorestorative therapies

Regenerative Biology for Healthier Lives

Investor Presentation

March 2024

Forward-Looking Statements

Statements in this presentation, including the information set forth as to the future financial or operating performance of BioRestorative Therapies, Inc. (the "Company") that are not current or historical factual statements may constitute "forward-looking" information within the meaning of the U.S. federal and state securities laws. When used in this presentation, such statements may include, among other terms, such words as "may," "will," "expect," "believe," "plan," "anticipate," "intend," "estimate," "project," "target" and other similar terminology. These statements reflect current expectations, estimates and projections regarding future events and operating performance and speak only as to the date of this presentation. Readers should not place undue importance on forward-looking statements and should not rely upon this information as of any other date.

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, business plan or industry results, to differ materially from our expectations of future results, performance or achievements expressed or implied by these forward-looking statements. These forward looking statements may not be realized due to a variety of factors, including without limitation: (i) our limited operating history, lack of significant revenues, and substantial losses since inception;(ii) our ability to obtain sufficient financing to initiate and complete our clinical trials and fund our operations; (iii) our ability to timely and successfully develop and commercialize BRTX-100, our lead product candidate for the treatment of chronic lumbar disc disease; (iv) delays in enrolling patients in our clinical trials; (v) disruption to our access to the media (including cell culture media) and reagents the Company is using in the clinical development of our cell therapy product candidates; (vi) failure of our clinical trials to demonstrate adequately the safety and efficacy of our product candidates; (vii) our lack of manufacturing capabilities to produce our product candidates at commercial scale quantities and lack of an alternative manufacturing supply; (viii) a loss of our exclusive license rights with regard to our disc/spine technology; (ix) safety problems encountered by us or others developing new stem cell-based therapies; (x) ethical and other concerns surrounding the use of stem cell therapy which negatively impact the public perception of our stem cell products and/or services; (xi) our limited experience in the development and marketing of cell therapies; (xii) our reliance on novel technologies that are inherently expensive and risky; (xiii) significant product liability claims and litigation to which the company may be subject, including potential exposure from the use of our product candidates in human subjects; (xiv) our inability to obtain reimbursement for our products and services from private and governmental insurers; (xv) our inability to protect our proprietary rights; and (xvi) compliance with applicable federal, state, local, and international requirements. See also "management's discussion and analysis of financial condition and results of operations – factors that may affect future results and financial condition" set forth in the Company's most recent annual report filed with the SEC.

Many of these issues can affect the Company's actual results and could cause the actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, the Company. You are cautioned that forward-looking statements are not guarantees of future performance, and you should not place reliance on them. In formulating the forward-looking statements contained in this presentation, it has been assumed that business and economic conditions affecting the Company and the economy generally will continue substantially in the ordinary course. These assumptions, although considered reasonable at the time of preparation, may prove to be incorrect.

The description of the Company and its business in this presentation does not purport to be complete and is subject to the more detailed description of the Company and its business in the Company's annual, quarterly and current reports filed with the SEC.

Fully Integrated Regenerative Medicine Company

DEVELOPMENT



ThermoStem	BRTX-100
Brown adipose derived stem cells	Bone marrow derived mesenchymal stem cells
PRECLINICAL	MID-STAGE CLINICAL

COMMERCIAL

Secretome (novel exosome, growth factor/cytokine) biologics based technology for cosmetic applications

Experienced Leadership

Lance Alstodt
Chairman & CEO

- 30+ years leading, advising and operating companies within the Healthcare sector
- Founder of MedVest Capital, a Healthcare fund created in 2013
- Prior to that led the Medical Technology investment banking group at Bank of America Merrill Lynch and Leerink Partners

Robert Kristal
Chief Financial Officer

- 25+ years on Bay Street and Wall Street
- Most recently was the DOR for a Healthcare focused Investment Bank
- Career has spanned Trading, Sales, Investment Banking and Research

Francisco Silva
Vice President of R&D

- 20+ years in the R&D of cell-based and off-the-shelf therapeutics
- As BRTX's Vice President R&D, established high throughput Stem Cell Research Program based on his academic and industrial research experience
- Has obtained several patents in cell therapy, and has manuscripts published with regards to translational stem cell research

Bob Paccasassi
Vice President of Quality

- 25+ years of biotech operations and combined experience in Quality Assurance, Regulatory, and Manufacturing (QRM)
- Previous QRM management positions at Regeneron, Millennium, and Merck

DEVELOPMENT

ThermoStem

Brown adipose derived stem cells

PRECLINICAL

BRTX-100

Bone marrow derived mesenchymal stem cells

MID-STAGE CLINICAL

COMMERCIAL

BioCosmeceuticals

Secretome (novel exosome, growth factor/cytokine) biologics based technology for cosmetic applications

Going Commercial: Biologics Based Cosmetic Products

Key Features of Cosmetics & Hair Growth Biologics Products

The Market

- Global Cosmetic market $63 B and growing
- Global injectable market 12% CAGR 2021-2026 Est $11.9 B
- Derms need differentiated product
- Bundle with current procedures

Manufacturing

- cGMP ISO 7 Certified Facility
- Cellular Biology Engineering Expertise
- Multi use facility highlights versatility

Products

- Cell based biologics engineered and targeted for both clinical and aesthetic use.

DEVELOPMENT



Brown adipose derived stem cells	Bone marrow derived mesenchymal stem cells
PRECLINICAL	MID-STAGE CLINICAL

COMMERCIAL

Secretome (novel exosome, growth factor/cytokine) biologics based technology for cosmetic applications

Robust Preclinical & Clinical Pipeline



* Polycystic ovarian syndrome
** Acute respiratory distress syndrome
*** Expected approval Q2 2024

Chronic Lumbar Disc Disease (cLDD)

258 M	U.S. adult population
64.5 M	American adults with chronic lower back pain prevalence
32 M	American adults with diagnosed and treated disc degeneration
15 M	Americans suffering pain caused by a protruding or injured disc
2.5 M	Invasive Surgical Procedures per year **$40 billion** in surgeries



* Trinity Partners Report, "Degenerative Disc Disease US Market Assessment (Phase I)," Feb. 2016, Slide 9 of report.

The Problem: Clinical & Economic



Our Solution: BTRX-100



BRTX-100: Clinical Snapshot

Lead investigational therapeutic product

Autologous (patient's own) cell-based biologic

Hypoxic (low oxygen) cultured, bone marrow-derived

Single intradiscal injection – anticipated 30 minute in-office procedure

Prior human data provides insight into the potential safety and efficacy of BRTX-100

FDA authorized commencement of Phase 2 clinical trial

Large growing market with few comparable autologous therapies

1) Trinity Partners Report, "Degenerative Disc Disease US Market Assessment (Phase I)," Feb. 2016, Slide 9 of report.

BRTX-100: Key Differentiating Factors

	mesoblast	biorestorative therapies
SOURCE	**Allogeneic** uses human derived stem cells (not from patient) - 6 million	**Autologous** uses patients own stem cells - 40 million
CULTURING	**Normoxic cultured** with normal oxygen environment (~20%)	**Hypoxic cultured** in low oxygen environment (5%)
CARRIER	**Hyaluronic Acid Carrier**	**Autologous Platelet Lysate Carrier & Adjuvant**
MANUFACTURING	**Animal Products Used**	**100% Animal-Free**

BRTX-100 Advantages

- Autologous cells means low to no risk of rejection, greater safety profile (introduction of viral/genetic), potentially streamlined regulatory path
- Hypoxic culturing creates increased cell proliferation, greater plasticity, increased paracrine effect and increased cell survival after application
- Autologous platelet lysate provides growth factors that interact with the cells, allowing for better cell survival
- Low to no risk of safety concerns related to immunological and zoonotic (animal to people) transmission
- Strong runway for value creation with successful clinical results

BRTX-100: Positive Human Data

Human data from studies of therapies similar to BRTX-100 show reduced pain, increased function, and an absence of significant safety issues with a durable response



Centeno et al. J Transl Med (2017) 15:197
DOI 10.1186/s12967-017-1300-y

Journal of Translational Medicine

RESEARCH — Open Access

Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy

Christopher Centeno[1,2], Jason Markle[1], Ehren Dodson[2*], Ian Stemper[2], Christopher J. Williams[1], Matthew Hyzy[1], Thomas Ichim[3] and Michael Freeman[4]



Original Clinical Science—General

Intervertebral Disc Repair by Allogeneic Mesenchymal Bone Marrow Cells: A Randomized Controlled Trial

David C. Noriega, MD, PhD,[1] Francisco Ardura, MD, PhD,[1] Rubén Hernández-Ramajo, MD, PhD,[1] Miguel Ángel Martín-Ferrero, MD, PhD,[1] Israel Sánchez-Lite, MD,[2] Borja Toribio, MD,[2] Mercedes Alberca, PhD,[3] Verónica García, PhD,[3] José M. Moraleda, MD, PhD,[4] Ana Sánchez, MD, PhD,[5] and Javier García-Sancho, MD, PhD[5]



Kumar et al. Stem Cell Research & Therapy (2017) 8:262
DOI 10.1186/s13287-017-0710-3

Stem Cell Research & Therapy

RESEARCH — Open Access

Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study

Hemant Kumar[†1], Doo-Hoe Ha[†2], Eun-Jong Lee[†1], Jun Hee Park[4], Jeong Hyun Shim[4], Tae-Keun Ahn[5], Kyoung-Tae Kim[6], Alexander E. Ropper[7], Sell Sohn[1], Chung-Hun Kim[8], Devang Kashyap Thakor[9], Soo-Hong Lee[10*] and In-Bo Han[1*]

Stem Cells and Development > Vol. 28, No. 17 > Original Research Reports

The Traceability of Mesenchymal Stromal Cells After Injection Into Degenerated Discs in Patients with Low Back Pain

Helena Barreto Henriksson, Nikolaos Papadimitriou, Daphne Hingert, Adad Baranto, Anders Lindahl, and Helena Brisby

Anders Lindahl

Published Online: 23 Aug 2019 | https://doi.org/10.1089/scd.2019.0074

biorestorative therapies

BRTX-100: Phase 2 Trial Design

FDA Cleared IND 17275:
Phase 2 Randomized, Controlled Study Design in Patients with cLDD

Design

- Study includes 99 subjects (2:1 product to placebo)
- 40.000.000 cells/dose
- Included subjects will have only one symptomatic diseased disc

Primary Efficacy Endpoint

12 m, F/U at 24 m

Improvement in function:
at least 30% increase in function based on Oswestry Disability Index questionnaires (ODI)

Reduction of pain:
at least 30% decreased in pain as measured using a Visual Analogue Scale (VAS)

Patient Population

- Subjects must have current diagnosis of cLDD, typical pain with degeneration of a single disc confirmed by history, exam, radiography, or other acceptable means
- Subjects will have exhausted previous conservative non-operative therapies

BRTX-100: Logistical /Clinical Process



BRTX-100: Cleared DSMB June 2023

- Unanimous approval by the DSMB to continue trial without changes
- BRTX-100 is safe and well tolerated
- All 4 subjects successfully dosed with either 40 mil hMSCs or placebo
- First time 40 million cells injected in a human subject
- 3:1 randomization
- No Significant Adverse Events
- VAS, ODI, SF-12, RMDQ, and FRI scores to measure pain and function were collected
- Opportunity to leverage this data and clinical package

Preliminary Phase 2 Clinical Data: Meaningful Signals

"Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease, Initial Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells,"

presented at ORS 2024

- 4 subjects underwent successful dosing of either a 40 × 10^6 cell dose of hMSCs or saline at a 3:1 randomization ratio
- All AEs where non-serious and related to expected increased post-procedural back pain. The 2 remaining subjects of the safety run-in cohort did not experience any AEs/SAEs during and post dosing of either a 40 ×10^6 cell dose of hMSCs or saline
- Patient reported outcomes VAS, ODI, RMDQ, and FRI used to measure pain and function were also collected during the safety run-in period

Raw Data


FRI
VAS
ODI
RMDQ
100
80
60
40
20
0
Baseline
wk 2
wk 12
wk 26
wk 52
Subject 1
Subject 2
Subject 3
Subject 4

Relative Change



ThermoStem Program: Allogeneic Cell-based Therapy

Target Conditions: Obesity, Type 2 diabetes, and Metabolic disorders

Cell Type: Brown Fat

- Has been shown to regulate metabolic homeostasis in the body

Components of Library:

- Human Brown Adipose Tissue (BAT)
- White Adipose Tissue (WAT)
- Brown Adipose-derived Stem Cells (BADSC)

Initial Proof of Concept:

✓ Completed in small animal model

Patent Portfolio: Related BAT patent portfolio, including issued patents in the U.S., Australia and Japan

Platform Program:

For the development of cell & small molecule therapies



Metabolic Program Highlights



- First human stem cell derived BAT transfer
- Creation of first human 3D engineered artificial brown adipose tissue construct (aBAT)
- Successful delivery of 3D aBAT construct in mouse model
- Transplantation of aBAT lowered blood glucose levels
- Transplantation of aBAT decreased weight in obese mice
- Published initial proof of concept completed

Metabolic Program Clinical Pathway

File DMF with FDA

Expect filing a Drug Master File ("DMF") with the FDA to facilitate licensing opportunities around ThermoStem.

Pre-IND Meeting with FDA

Scheduling Pre-IND meeting with FDA to discuss first-in-man fast-track regulatory pathways.

Initiate Phase 1/2 Clinical Trial

Upon FDA approval commence Phase 1/2 clinical trial.

Our Opportunities are Well-Protected

PROGRAM	brtx disc	ThermoStem
INDICATION	Disc / Spine	Metabolic
PATENT TITLES	• Methods and Compositions to facilitate repair of avascular tissue • Surgical Methods and Compositions to facilitate repair of avascular tissue • Therapeutic Delivery Device	• Brown Fat Compositions and Methods • Human Brown Adipose Derived Stem Cells and Uses • Non-naturally occurring three-dimensional (3D) Brown Adipose-Derived Stem Cell aggregates and methods of generating and using the same
NO. OF APPLICATIONS	12	25
STATUS	2 Issued 10 Pending	17 Issued 9 Pending

Scientific Advisory Board

Wayne Marasco, MD, PDt
Chairman of SAB

- Principal Faculty Member of Harvard Stem Cell Institute
- Professor in the Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute
- Professor of Medicine at Harvard Medical School

Jason Lipetz, MD
Chairman of SAB Sub Committee
Disc Advisory Board

- Chief of Spine Medicine for the Northwell Health Spine Center
- Founder of Long Island Spine Rehabilitation Medicine

Harvinder Sandhu, MD
Member Disc Advisory Board

- Orthopedic Spine Surgeon at the Hospital for Special Surgery
- Specializes in minimally invasive spine surgery, endoscopic spine surgery, microsurgery, computer-assisted surgery, and the study and use of spinal biologics

Wayne Olan, MD Clinical
Director of Regenerative Disc / Spine Program

- Board-certified Interventional Neuroradiologist
- Director of Endovascular and Minimally Invasive Neurosurgery at the George Washington University Medical Center

Christopher Plastaras, MD
Member Disc Advisory Board

- MossRehabs' Clinical Director of Musculoskeletal Spine & Sports Rehabilitation Medicine

Joy Cavagnaro, PhD
Member

- President and Founder of Access BIO, L.C.
- Previously positions with the FDA Center for Biologics Evaluation and Research (CBER), for a decade

Financial Summary

Common Shares Outstanding	**6.7 Million**
Cash	**$ 12.2 Million** *
Debt	**$0**

* As of 09/30/2023; does not include approx. net proceeds of $7.6 million from 02/06/2024 warrant exchange

2023 Accomplishments

- Expanded ThermoStem patent portfolio in U.S. and Japan
- Two Notice of Allowances
- Completed 4 patient Safety Run-in component for Phase 2
- Announced a filing and execution of an ATM
- Announced Northwell Healthcare Partnership – Largest Healthcare System in the Northeast
- Cleared first DSMB
- Closed a $2.1 Million Registered Direct financing
- Enhanced shareholder profile with small institutions and family offices
- Leveraged our expertise in Regenerative Medicine in our FDA company, ISO-7 cGMP certified to manufacture advanced logistic products of maximum potency and efficacy

BRTX cGMP Clean Room

Upcoming Milestones: Provide Multiple Potential Value Inflection Points

PLATFORM	PROGRAM/ACTIVITY	SITUATION OVERVIEW
Cell-Based Secretome Derived	Skin remodeling, facial application /hair growth	• Regenerative Cosmetic & Aesthetic treatment to rejuvenate skin and grow hair
BRTX-100	cLDD	• Anticipate providing updates on sites/enrollment and preliminary data (still blinded) • Phase 2 Cervical IND approval
Brown Fat Derived Adipose Tissues	Obesity, PCOS and Metabolic Disorders	• Advance this technology through DMF and IND
	Expand Patent Portfolio	• Additional patents announcements - Brown Fat • Provisional Patent around BRTX-200 (next generation)

In Conclusion

- cGMP ISO-7 Certified Clean room
- Disruptive Platform Technologies in Cellular Therapy
- Strong Preliminary Data Indicative of Positive Trial Outcomes
- Active Phase 2 Trial in Spine
- Addressing Multi-Billion Dollar Markets with Unmet Needs
- Opportunity for Key Strategic Partnerships in Cosmetic Space
- Strong Intellectual Property Protection
- Experienced Management Team & Scientific Advisory Board

biorestorative
therapies

40 Marcus Drive, Suite 1
Melville, NY 11747

(631) 760-8100

biorestorative.com